TransMed7’s Intellectual Property portfolio is built on a robust patent generation and protection strategy, developed and backed by deep expertise with our patent prosecution and litigation experts. All patents are owned by TransMed7, LLC – Exclusive Technology Licenses are granted to Project Company’s by TransMed7. Licenses are exclusive, fully paid up, world-wide, royalty free.
TransMed7 continues to strengthen its intellectual property position with seven granted U.S. patents and two granted international patents for our SpeedBird and Concorde platform devices, three granted U.S. patents and two granted international patents for our Martinet whole lesion excisional technology, two granted U.S. patents for our Cardinal fine needle core biopsy platform devices, and one granted U.S. patent for our new ColibriTM fine needle material delivery platform. Moreover, we have 15 pending U.S. patents and 21 pending international patents centered on next generation, minimally invasive biopsy devices.
With these patents in place and more in the pipeline, TransMed7 continues to develop and secure new paradigm technologies that will transform tissue acquisition procedures and protects these technologies around the globe through international patent bodies.
